Xu Min, Li Dong, Yang Chen, Ji Jian-Song
Key Laboratory of Imaging Diagnosis and Minimally Invasive Intervention Research, The Fifth Affiliated Hospital of Wenzhou Medical University, Affiliated Lishui Hospital of Zhejiang University, Lishui Municipal Central Hospital, Lishui, China.
Clinical Laboratory, Shanghai Tongji Hospital, Tongji University School of Medicine, Shanghai, China.
Cell Physiol Biochem. 2018;46(3):1286-1304. doi: 10.1159/000489111. Epub 2018 Apr 16.
BACKGROUND/AIMS: Breast cancer (BC) starts as a local disease, but it can metastasize to the lymph nodes and distant organs. However, the metastatic process is still poorly understood. The mRNA microarray datasets GSE26910 and GSE33447 show that CXCL10 is up-regulated in BC, and the microRNA microarray dataset GSE38167 and a network meta-analysis of microRNA expression profile studies in human BC suggest that microRNA-34a (miR-34a) is down-regulated in BC. CXCL10 was predicted as a target of miR-34a by microRNA.org. In this study, we uncovered a CXCL10-independent mechanism by which miR-34a exerts its antimetastatic activity in BC.
To investigate the clinical significance of miR-34a in BC, we collected cancer tissues and paracancerous tissues from 258 patients with BC. In addition, a series of inhibitors, mimics, and siRNAs was introduced into MCF-7 and T47D cells to validate the regulatory mechanisms by which miR-34a regulates CXCL10. Next, to better understand the pivotal role of TLR signaling pathway inhibition in MCF-7 and T47D cells, we blocked the TLR signaling pathway using OxPAPC, an antagonist of TLR signaling.
Among BC patients, miR-34a was down-regulated, CXCL10 was up-regulated, and the TLR signaling pathway was activated. Determination of luciferase activity revealed that CXCL10 was a target of miR-34a. Through gain- and loss-of-function studies, miR-34a was demonstrated to negatively regulate CXCL10; inhibit activation of the TLR signaling pathway; significantly suppress in vitro cell proliferation, migration, and invasion; and induce apoptosis.
Our findings suggest that functional loss or suppression of the tumor suppressor CXCL10 due to induction of miR-34a leads to inhibition of the TLR signaling pathway during breast tumorigenesis, providing a novel target for the molecular treatment of breast malignancies.
背景/目的:乳腺癌(BC)起初是一种局部疾病,但可转移至淋巴结和远处器官。然而,转移过程仍未被充分了解。mRNA微阵列数据集GSE26910和GSE33447显示,CXCL10在BC中上调,而微RNA微阵列数据集GSE38167以及一项针对人类BC微RNA表达谱研究的网络荟萃分析表明,微RNA-34a(miR-34a)在BC中下调。通过microRNA.org预测CXCL10是miR-34a的一个靶标。在本研究中,我们发现了一种不依赖CXCL10的机制,通过该机制miR-34a在BC中发挥其抗转移活性。
为研究miR-34a在BC中的临床意义,我们收集了258例BC患者的癌组织和癌旁组织。此外,将一系列抑制剂、模拟物和小干扰RNA(siRNA)导入MCF-7和T47D细胞,以验证miR-34a调节CXCL10的调控机制。接下来,为更好地理解Toll样受体(TLR)信号通路抑制在MCF-7和T47D细胞中的关键作用,我们使用TLR信号拮抗剂氧化型1-棕榈酰-2-油酰-sn-甘油-3-磷酸胆碱(OxPAPC)阻断TLR信号通路。
在BC患者中,miR-34a下调,CXCL10上调,且TLR信号通路被激活。荧光素酶活性测定显示CXCL10是miR-34a的一个靶标。通过功能获得和功能缺失研究表明,miR-34a负向调节CXCL10;抑制TLR信号通路的激活;显著抑制体外细胞增殖、迁移和侵袭;并诱导细胞凋亡。
我们的数据表明,由于miR-34a的诱导导致肿瘤抑制因子CXCL10功能丧失或受抑制,从而在乳腺肿瘤发生过程中抑制TLR信号通路,为乳腺恶性肿瘤的分子治疗提供了一个新靶点。